Accessibility Menu
HeartFlow logo

HeartFlow(NASDAQ) HTFL

Market Cap$4.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+75%
5 YearN/A
1 Year+60%
1 Month+100%
$50.35
-0.08%
-0.04Today
After hours$50.40+$0.04 (+0.09%)
HeartFlow last closing stock price
MetricPriceDate
Last closeUSD 50.432026-09-01
HeartFlow stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.08%USD 49.892026-08-25
1 month+99.88%USD 25.232026-07-31
3 month+74.8%USD 28.852026-06-03
Year to date+73%USD 29.152025-12-31
1 year+60.1%USD 31.502025-08-29
Since inception+75.41%USD 28.752025-08-08

HeartFlow Financials at a Glance

Market Cap

$4.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$212.08M

Net Income (TTM)

-$118.37M

EPS (TTM)

-$1.40

P/E Ratio

-36.09

Dividend

$0.00

Beta (Volatility)

1.80 (High)

Price

$50.35

Volume

1,678,851.196

Open

$50.28

Previous Close

$50.43

Daily Range

$49.21 - $50.99

52-Week Range

$20.13 - $51.19

Estimated Earnings Date

Nov 11, 2026

HTFL News

SellAlert-Green.png

HeartFlow's Chief Medical Officer Sells 9,219 Shares Amid a Soaring Stock Price. What Does That Mean for Investors?

Robert IzquierdoAug 20, 2026
Healthcare - GettyImages-1390886692-1500x1000-6b42342

Why Heartflow Stock Soared Today

Joe TenebrusoAug 14, 2026
SellAlert-Purple.png

What Does the HeartFlow CEO's Sale of Over 20,000 Company Shares Mean for Investors?

Robert IzquierdoJul 15, 2026
TMF-Pills-Blue-StockVStock.png

Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?

Brendan CoffeyJul 8, 2026
TMF-Pills-Green-StockVStock.png

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Brendan CoffeyJul 4, 2026
TMF-Pills-Purple-StockVStock.png

HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?

Brendan CoffeyJun 24, 2026
BuyAlert-Purple.png

Is HeartFlow Stock a Buy After an Institutional Investor Initiated a Position Worth $2.7 Million?

Robert IzquierdoMay 31, 2026
bull on a rising stock chart

Wall Street Waits for the SpaceX IPO, These 2 Under-the-Radar IPOs Could Already Be Making You Money

Leo SunMay 12, 2026
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About HeartFlow

HeartFlow, Inc. helps doctors find heart disease using 3D maps. These digital models show blood flow from a single scan. Patients can avoid surgery for diagnosis using this technology.

Mapping the Human Heart

  • FFRCT Analysis: Calculates blood flow and identifies blockages; represents nearly all cumulative revenue to date.
  • Plaque Analysis: Provides assessments of coronary plaque; began using expanded reimbursement on Jan. 1, 2026.
  • RoadMap Analysis: Visualizes coronary arteries for physicians; functions as an integrated efficiency tool rather than a standalone product.
  • PCI Navigator: Assists in planning revascularization procedures; launched in April 2026 as an integrated feature.

Recent Strategic Steps

  • Launched HeartFlow PCI Navigator in April 2026 to help physicians plan artery procedures.
  • Completed an initial public offering on Aug. 11, 2025, raising approximately $332.4 million in net proceeds.
  • Repaid $60.1 million in outstanding debt under its 2024 Credit Agreement in August 2025.
  • Subleased its Mountain View, California facility in March 2026.

What Makes HeartFlow Different

The platform requires no heavy equipment and uses cloud-based artificial intelligence to process scans. This approach has allowed the technology to assess more than 750,000 patients as of June 30, 2026.

A Look at the Numbers

  • Revenue was $64.1 million for the three-month period ended June 30, 2026, up 48% year over year.
  • Revenue case volume reached 84,491 in the three-month period ended June 30, 2026, up 74% year over year.
  • Gross margin reached 83% for the three-month period ended June 30, 2026.
  • Net loss was $15.7 million for the three-month period ended June 30, 2026, widening 71% year over year.
  • Cash, cash equivalents, and investments totaled $246.8 million as of June 30, 2026.

Bottom Line

HeartFlow has transitioned from a private research firm to a public company scaling its heart imaging software. The business is now shifting toward plaque analysis and procedural planning to expand its role in cardiac care.

AI Generated • Aug 14, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

843

CEO

John C. M. Farquhar, MBA

Website

www.heartflow.com

Headquarters

San Francisco, CA 94105, US

HTFL Financials

Key Financial Metrics (TTM)

Gross Margin

80.08%

Operating Margin

-34.31%

Net Income Margin

-55.82%

Return on Equity

-42.25%

Return on Capital

-19.85%

Return on Assets

-34.36%

Earnings Yield

-2.77%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

86.95M

Volume

1.68M

Avg. Volume

1.80M

Financials (TTM)

Gross Profit

$169.83M

Operating Income

-$72.77M

EBITDA

-$108.23M

Operating Cash Flow

-$52.23M

Capital Expenditure

-$6.95M

Free Cash Flow

-$59.18M

Cash & ST Invst.

$162.55M

Total Debt

$27.13M

HeartFlow Performance Analysis

HeartFlow annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-12-31USD 87,174,000N/A
20242024-12-31USD 125,808,00044.3%
20252025-12-31USD 176,034,00039.9%
HeartFlow sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-306.6%
Q42025-12-316.2%
Q12026-03-317.0%
Q22026-06-3021.9%
HeartFlow annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-12-31USD -1.52N/A
20242024-12-31USD -1.19-22.0%
20252025-12-31USD -1.3715.3%
HeartFlow sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-472.7%
Q42025-12-3154.0%
Q12026-03-31-10.3%
Q22026-06-3043.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$64.08M

+47.6%

Gross Profit

$53.19M

+62.3%

Gross Margin

83.00%

N/A

Market Cap

$4.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.20M

N/A

Employees

843

N/A

Net Income

-$15.74M

-71.2%

EBITDA

-$15.72M

-4137.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$162.55M

+102.7%

Total Debt

$27.13M

-86.8%

Accounts Receivable

$42.76M

+33.0%

Inventory

$0.00

N/A

Long Term Debt

$20.34M

-89.8%

Short Term Debt

$6.78M

+23.5%

Return on Assets

-34.36%

N/A

Return on Invested Capital

-24.23%

N/A

Free Cash Flow

-$10.50M

+62.6%

Operating Cash Flow

-$8.58M

+68.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LIVNLivaNova PLC
$80.16+0.44%
LEGNLegend Biotech Corporation
$21.13+1.68%
TARSTarsus Pharmaceuticals, Inc.
$74.05-0.26%
IRONDisc Medicine, Inc.
$78.67+0.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$14.06+0.06%
NVDANvidia
$217.44-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.33-0.06%
INTCIntel
$88.97-0.01%

Questions About HTFL

What is the current price of HeartFlow?

HeartFlow is trading at $50.43 per share.

What is the 52-week range for HeartFlow?

Over the past 52 weeks, HeartFlow has traded between $20.13 and $51.19.

How much debt does HeartFlow have?

As of the most recent reporting period, HeartFlow reported total debt of $27.13M.

How much cash does HeartFlow have on hand?

HeartFlow reported $34.36M in cash and cash equivalents in its most recent financial results.

What is HeartFlow’s dividend yield?

HeartFlow does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services